Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

Inclusion Criteria Concurrent Medication: Allowed: * Inhalation pentamidine for the prevention of Pneumocystis carinii pneumonia (PCP) at a dose of 300 mg once every 4 weeks. * AMENDED: Trimethoprim - sulfamethoxazole or dapsone only if on the maintenance phase of the study. Concurrent Treatment: Allowed: * Blood transfusions. Patients must have a positive antibody to HIV by any federally licensed ELISA test. All lab tests must be within 7 days of entry into the study. Exclusion Criteria Concurrent Medication: Excluded: * Other antiretroviral agents. * Immunomodulators. * Corticosteroids. * Cytotoxic chemotherapy. * Aspirin. * H2 blockers. * Barbiturates and myelosuppressive drugs should be particularly avoided as they may interfere with the metabolism or enhance the toxicities of either zidovudine or interferon alfa-2a. * Other experimental medications. Concurrent Treatment: Excluded: * Radiation therapy. Patients with prior experience of Grade 4 toxicity to zidovudine therapy will be excluded from the study. Prior Medication: Excluded: * Interferon therapy. * Excluded within 30 days of study entry: * Immunomodulators. * Corticosteroids. * Cytotoxic chemotherapeutic agents. * Excluded within 14 days of study entry: * Zidovudine (AZT). Prior Treatment: Excluded within 30 days of study entry: * Blood transfusions. * Radiation therapy. Patients may not have any of the following diseases or symptoms: * Active opportunistic infection associated with AIDS. *…